Replimune Group, Inc.

REPL ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Assets
Cash & Equivalents $209.0M $111.1M $74.5M $146.6M $105.9M $182.5M $59.5M $25.7M
Accounts Receivable — — — — — — — —
Inventory — — — — — — — —
Total Current Assets $279.1M $495.9M $433.7M $592.6M $404.0M $483.7M $174.3M $141.0M
Property, Plant & Equipment $13.0M $13.7M $10.5M $7.5M $7.9M $7.4M $6.9M $12.2M
Goodwill — — — — — — — —
Intangible Assets (Excl. Goodwill) — — — — — — — —
Total Assets $332.4M $551.3M $487.7M $646.6M $461.2M $543.1M $234.1M $154.3M
Liabilities
Accounts Payable $6.7M $12.5M $2.6M $5.4M $3.7M $2.4M $3.4M $7.1M
Total Current Liabilities $58.2M $62.4M $40.4M $33.8M $20.8M $14.5M $11.9M $9.9M
Long-Term Debt $83.3M $46.4M $44.8M $28.6M $0 — $9.8M —
Total Liabilities $166.2M $135.5M $113.2M $91.3M $50.0M $44.4M $50.4M $16.5M
Stockholders' Equity
Retained Earnings $-1.26B $-948.6M $-701.3M $-485.5M $-311.2M $-193.2M $-112.3M $-59.8M
Total Stockholders' Equity $166.2M $415.8M $374.5M $555.3M $411.2M $498.7M $183.7M $137.9M
← Newer Page 1 of 2 Older →